Prevention of obesity and type 2 diabetes mellitus: What can we do?;Prävention von übergewicht und diabetes mellitus typ 2: Was können wir tun?

Arzneimitteltherapie

Volumn 26, Issue 9, 2008, Pages 323-331

  Steveling, Antje ^a   Schipf, Sabine ^a   Lerch, Markus M ^a   Lohmann, Tobias ^b   Völzke, Henry ^a   Wallaschofski, Henri ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Abteilung für Innere Medizin des Städtischen Krankenhauses Dresden Neustadt   (Germany)

Author keywords

Diabetes mellitus type 2; Lifestyle intervention; Prevention

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; NEBIVOLOL; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE;

CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; ECONOMIC ASPECT; FINLAND; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; LIFESTYLE MODIFICATION; LONGITUDINAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; UNITED STATES;

EID: 77953434365     PISSN: 07236913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
2. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14:S1-85.
3. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-31.
4. Fagot-Campagna A, Narayan K. Type 2 diabetes in children. BMJ 2001;322:377-87.
5. Kiess W, Böttner A, Raile K, Kapellen T, et al. Type 2 diabetes mellitus in children and adolescents: a review from a European perspective. Horm Res 2003;59(Suppl 1):77-84.
6. Rosenbloom A, Joe J, Young R, Winter W. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999;22:345-54.
7. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Report no.: WHO/NCD/NCS/99.2. Geneva: Department of Non-communicable Disease Surveillance, World Health Organization, 1999.
8. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-21.
9. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-23.
10. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32.
11. Finkelstein EA, Fiebelkorn IC, Wang G. State-level estimates of annual medical expenditures attributable to obesity. Obes Res 2004;12:18-24.
12. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1977. Diabetes Care 1998;21:296-309.
13. Harris M, Flegal K, Cowie C, Eberhardt M, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey 1988-1994. Diabetes Care 1998;21:518-24.
14. Colditz G, Willett W, Rotnitzky A, Manson J. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
15. Pi-Sunyer F. Comorbidities of overweight and obesity: current evidence and research issues. Med Sci Sports Exerc 1999;31:S602-8.
16. United Kingdom Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
17. Zimmet P. Diabetes epidemiology as a trigger to diabetes research. Diabetologia 1999;42:499-518.
18. Uusitupa M. Lifestyles matter in the prevention of type 2 diabetes. Diabetes Care 2002;25:1650-1.
19. Hu FB, Manson JE, Stampfer MJ, Colditz G, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-7.
20. Despres J. The insulin resistance-dyslipidemic syndrom of visceral obesity: effect on patients. Risk Obes Res 1998;6(Suppl 1):8S-17S.
21. Stanner S, Bulmer K, Andres C, Lantseva O, et al. Does malnutrition in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a cross sectional study. BMJ 1997;315:1342-9.
22. Pan X, Li G, Hu Y, Wang J, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT Diabetes Study. Diabetes Care 1997;20:537-44.
23. Tuomilehto J, Lindstrom J, Eriksson J, Valle T, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
24. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002:346:393-403.
25. Palmer AJ, Roze S, Comte S, Cabrieres L. Cost-effectiveness of intensive lifestyle changes or metformin overnight, glucose intolerant patients: modelling the long-term implications of the diabetes prevention program in the French, German and UK settings. Diabetologia 2002;45:938.
26. Jeon CY, Lokken RP, Hu FB, Van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes. Diabetes Care 2007;30:744-52.
27. Weinstein AR, Sesso HD, Lee IM, Cook NR, et al. Relationship of physical activity vs. body mass index with type 2 diabetes in women. JAMA 2004;292:1188-94.
28. Hsia J, Wu L, Allen C, Oberman A, et al. Physical activity and diabetes risk in postmenopausal women. Am J Prev Med 2005;28:19-25.
29. Baan CA, Stolk RP, Grobbee DE, Witteman JC, et al. Physical activity in elderly subjects with impaired glucose tolerance and newly diagnosed diabetes mellitus. Am J Epidemiol 1999;149:219-27.
30. Van Dam RM, Schuit AJ, Feskens EJ, Seidell JC, et al. Physical activity and glucose tolerance in elderly men: the Zutphen elderly study. Med Sci Sports Exerc 2002;34:1132-6.
31. Defay R, Delcourt C, Ranvier M, Lacroux A, et al. Relationships between physical activity, obesity and diabetes mellitus in a French elderly population: the POLA study. Int J Obes Relat Metab Disord 2001;25:512-8.
32. Okada K, Hayashi T, Tsumura K, Suematsu C, et al. Leisure-time physical activity at weekends and the risk of type 2 diabetes mellitus in Japanese men: the Osaka Health Survey. Diabet Med 2000;17:53-8.
33. Wing RR, Goldstein MG, Acton KJ, Birch LL, et al. Behavioural science research in diabetes: lifestyle changes related to obesity, eating behaviour, and physical activity. Diabetes Care 2001;24:117-23.
34. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, et al. Treatment of obesity by very low calorie diet, behaviour therapy, and their combination: a five-year perspective. Int J Obes Relat Metab Disord 1989;13:39-46.
35. Chiasson JL, Josse RG, Gomis R, Hanefeld M, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
36. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
37. Scheen AJ, Finer N, Hollander P, Jensen MD. Efficiency and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72.
38. Buchuchanan TA, Xiang AH, Peters RK, Kjos SL, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-803.
39. Gerstein HC, Yusuf S, Holman RR, Bosch J. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
40. Avandia (rosiglitazone maleate) tablets: prescribing information. Research Triangle Park, NC: GlaxoSmithKline, 2007 (package insert).
41. Kahn S, Haffner S, Heise M, Herman W, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. NEJM 2006:355:2427-43.
42. Nesto R, Bell D, Bonow R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association. Circulation 2003;108:2941-8.
43. Dormandy J, Charbonnel B, Eckland D. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89.
44. Goldberg R, Kendall D, Deeg M. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54.
45. Elliot W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.
46. Hansson L, Lindholm LH, Niskanen L, Lanke J, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
47. Heart Outcomes Prevention Evaluation (HOPE) Study. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
48. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
49. Freeman DJ, Norrie J, Sattar N, Neely RD, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
50. Gaede P, Vedel P, Larsen N, Jensen GVH, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
51. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
52. World Health Organisation. The European Health Report 2005: public health action for healthier children and population. Statistical tables. Geneva: World Health Organisation ed., 2005.
53. Cox HS, Williams JW, de Courten MP, Chitson P, et al. Decreasing prevalence of cigarette smoking in the middle income country of Mauritius: questionnaire survey. BMJ 2000;321:345-9.
54. Karagiannis E, Löbig M, Erdman E, Lübben G, et al. Prävalenz unentdeckter Diabeteserkrankungen bei Patienten von kardiologischen Schwerpunkteinrichtungen, www.ikfe.de